Bristol Myers Squibb announces strategic agreement with Anthropic to position Claude Enterprise as the shared intelligence platform across its global operations

BMS plans to deploy Claude broadly across the company, equipping more than 30,000 employees with advanced reasoning and agentic capabilities. The rollout focuses on three priorities where BMS anticipates the strongest near term impact.

The first is accelerating engineering with Claude Code. BMS’ engineering and data science teams will use Claude Code to speed up software and AI development, standardising how capabilities are built and deployed across the enterprise and unlocking data and expertise long held in disconnected systems.

The second is embedding agents into the workflows that move medicines forward. In research, this means applying advanced AI reasoning to decades of BMS’ proprietary scientific, molecular, and clinical data to accelerate target identification and optimisation across oncology, hematology, neuroscience, and immunology. In drug development, it means automating trial documentation, from clinical study reports and patient safety narratives to regulatory submissions, with the potential to shorten the time between data lock and filing. In manufacturing and quality, it means accelerating root cause investigation, Corrective and Preventive Action documentation, and data driven batch release decisions. In commercial and medical affairs, it means turning field insights into structured intelligence that enables more personalised and timely engagement with healthcare professionals.

The third is connecting Claude to the institutional knowledge that lives across BMS. Through secure integrations with the systems and repositories where BMS’ scientific, clinical, regulatory, and commercial expertise resides, Claude’s agentic capabilities will help surface and activate that knowledge where it is most needed, with full enterprise governance and audit controls in place.

“Artificial intelligence is the single most powerful opportunity we have to accelerate our mission today,” said Greg Meyers, EVP and Chief Digital & Technology Officer, Bristol Myers Squibb. “Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it. Anthropic’s Claude gives us the agentic capabilities, pace of innovation, and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients. The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI, and BMS intends to be one of them.”

“By giving employees access to Claude’s agentic capabilities, connected to thousands of data sources across the company, BMS is creating a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time,” said Eric Kauderer-Abrams, Head of Life Sciences, Anthropic. “In a regulated global enterprise, that means medicines reach patients faster, with BMS’ scientific depth and operational rigor accelerated by Claude agents at every step.”

---

---

Related Topics and Keywords

Anthropic, Bristol-Myers Squibb, claude